Track topics on Twitter Track topics that are important to you
50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injectionas a fluid and nutrient replenisher.Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an osmolarity of 2.53 mOsmol/mL(calc.), a pH of 4.2 (3.2 to 6.5) and may contain sodium hydroxide and/or hydrochloric acid for pH adjustment.The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as asingle-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit.Dextrose, USP is chemically designated C6H12O6• H2O (D-glucose monohydrate), a hexose sugar freely soluble in water. Dextrose,hydrous has the following structural formula:
Water for Injection, USP is chemically designated H2O .The syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slowrate which will have an insignificant effect on solution concentration over the expected shelf life. Solutions in contact with theplastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing wassupportive of the safety of the syringe material.
When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydratecalories.Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextroseinjection undergoes oxidation to carbon dioxide and water.Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adultrequirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration ofelectrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.
50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore bloodglucose levels.The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intakeis restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure properutilization of dextrose and avoid production of hyperglycemia.
A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence ofdelirium tremens if the patient is already dehydrated.Dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because ofthe possibility that pseudoagglutination of red cells may occur.
50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection.Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should beaware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients withchronic uremia and those with known carbohydrate intolerance.The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyteconcentrations, overhydration, congested states or pulmonary edema.Additives may be incompatible. Consult with pharmacist if available. When introducing additives, use aseptic technique, mixthoroughly and do not store.For peripheral vein administration:The solution should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.For central venous administration:Concentrated dextrose should be administered via central vein only after suitable dilution.
Do not use unless the solution is clear and seal is intact. Discard unused portion.Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrosesolutions. Blood electrolyte monitoring is essential and fluid and electrolyte imbalances should be corrected. Essential vitamins andminerals also should be provided as needed.To minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and if necessary, addinsulin.When a concentrated dextrose infusion is abruptly withdrawn, it is advisable to follow with the administration of 5% or 10% dextroseinjection to avoid rebound hypoglycemia.Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.Care should be exercised to insure that the needle is well within the lumen of the vein and that extravasation does not occur. Ifthrombosis should occur during administration, the injection should be stopped and corrective measures instituted.Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.Carcinogenesis, Mutagenesis, Impairment of Fertility:Studies with solutions in polypropylene syringes have not been performed to evaluate carcinogenic potential, mutagenic potential oreffects on fertility.Pregnancy Category C.Animal reproduction studies have not been conducted with dextrose. It is also not known whether dextrose can cause fetal harm whenadministered to a pregnant woman or can affect reproduction capacity. Dextrose should be given to a pregnant woman only if clearlyneeded.Nursing MothersIt is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should beexercised when 50% Dextrose Injection, USP is administered to a nursing mother.
Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/orloss of consciousness.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures andsave the remainder of the fluid for examination if deemed necessary.
In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures.See WARNINGS and PRECAUTIONS.
For peripheral vein administration:Injection of the solution should be made slowly.The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour. About 95% of thedextrose is retained when infused ata rate of 0.8 g/kg/hr.In insulin-induced hypoglycemia, intravenous injection of 10 to 25 grams of dextrose (20 to 50 mL of 50% dextrose) is usuallyadequate. Repeated doses and supportive treatment may be required in severe cases. A specimen for blood glucose determinationshould be taken before injecting the dextrose. In such emergencies, dextrose should be administered promptly without awaitingpretreatment test results.For central venous administration:For total parenteral nutrition 50% Dextrose Injection, USP is administered by slow intravenous infusion (a) after admixture withamino acid solutions via an indwelling catheter with the tip positioned in a large central vein, preferably the superior vena cava, or (b)after dilution with sterile water for injection. Dosage should be adjusted to meet individual patient requirements.Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyteconcentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants suchevaluation.The maximum rate of dextrose administration which does not result in glycosuria is the same as cited above.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, wheneversolution and container permit. See CONTRAINDICATIONS.
50% Dextrose Injection, USP is supplied in single-dose containers as follows:
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Revised: October, 2009Printed in USA EN-2278Hospira, Inc., Lake Forest, IL 60045 USA
General Injectables & Vaccines, Inc.
Haemonetics Anticoagulant Citrate Dextrose Solution
Diltiazem HCl 250 mg in 5% Dextrose 300 mL Bag
5% Dextrose Injection, USP
Morphine Sulfate 1 mg/mL in 5% Dextrose 100 mL Bag
Amiodarone HCl 900 mg Added to 5% Dextrose 500 mL Bag
The aim of this study was to evaluate the safe of 40% Dextrose oral administration on blood glucose concentration and to reducing of pain before painful procedures on healthy term neonate ...
Twenty participants with severe arthritis will be enrolled. For the first week participants will either be injected with dextrose or just have fluid withdrawn for testing. The remaining pa...
Participants with wrist pain on the little finger side of the wrist will received either usual care, consisting of ultrasound, specialized massage and stabilization exercises therapy for 6...
The objective of the present study is to compare the effectiveness of 5% dextrose, local corticosteroids injections and surgical release in patients with mild to moderate CTS. We hypothesi...
The posterior antebrachial cutaneous nerve (PACN) can be compressed between the deltoid and triceps, with resultant pain and dysfunction. The active treatment for this study will be injec...
Transitioning from whole blood (WB) to components developed from efforts to maximize donor yield. Components are advantageous for specific derangements, but treating hemorrhage with components require...
To determine the impact of incorporating dextrose gel in the treatment of neonatal hypoglycaemia (NH) and the role of feeding type in NH outcomes.
The objective of this study is to compare the reproductive performance of cows affected by clinical endometritis (CE) following treatment with an intrauterine infusion of 50% dextrose solutions (DEX) ...
N-butyl cyanoacrylate glue (n-BCA, Cerenovus, Irvine, California) is commonly used to treat arteriovenous malformation (AVM). Even though Onyx (ethylene vinyl alcohol, Medtronic, Dublin, Ireland) pres...
Sepsis is characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection and affects over 1 million Americans annually. Loss of glycemic control in sepsis is a...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...